Affiliation:
1. Department of Medicine University of Miami Miller School of Medicine Miami Florida USA
2. Department of Pharmacy Sylvester Comprehensive Cancer Center Miami Florida USA
3. Department of Medicine, Division of Infectious Diseases University of Miami Miller School of Medicine Miami Florida USA
4. Division of Transplantation and Cellular Therapy Sylvester Comprehensive Cancer Center Miami Florida USA
5. Division of Hematology and Oncology, Department of Medicine UCSF Health and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco California USA
Abstract
AbstractBackgroundThe optimal number of doses as well as the role for measurement of postvaccination titers after measles, mumps, rubella (MMR) vaccination in adult hematopoietic cell transplantation (HCT) recipients remains unknown.MethodsIn the present study, we assessed humoral immunity against measles, mumps and rubella before and after MMR vaccination in 187 adults who received at least one dose of the MMR vaccine after HCT.ResultsAmong those with baseline titers, posttransplant prevaccination seroprotection rates were 56%, 30%, and 54% for measles, mumps, and rubella, respectively; and significantly lower in allogeneic versus autologous HCT recipients for measles (39% vs. 80%, p = .0001), mumps (22% vs. 41%; p = .02) and rubella (48% vs. 62%, p = .12). Among those who were seronegative at baseline, seroconversion rates after one dose of MMR were 69%, 56%, and 97% for measles, mumps, and rubella, respectively. Seronegative patients after one dose of MMR (i.e., nonresponders) seroconverted for measles and mumps after a second MMR vaccine dose.ConclusionOur findings demonstrate successful restoration of protective immunity against measles, mumps, and rubella after vaccination in adult HCT recipients; one dose of MMR elicited protective titers in the majority of patients, and a second vaccine dose was immunogenic in nonresponders.
image
Subject
Infectious Diseases,Transplantation
Reference16 articles.
1. Seroprevalence of Measles and Mumps Antibodies Among Individuals With Cancer
2. Long-term immunity to measles, mumps, and rubella after allogeneic bone marrow transplantation
3. Measles cases spike globally due to gaps in vaccination coverage. World Health Organization. Accessed April 22 2022.https://www.who.int/news/item/29‐11‐2018‐measles‐cases‐spike‐globally‐due‐to‐gaps‐in‐vaccination‐coverage
4. Early measles vaccination in bone marrow transplant recipients
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献